Bone Biologics Corporation - BBLG Short-Term Debt to Capital

Bone Biologics (BBLG) lacks pricing power, as its success depends on the results of ongoing clinical trials. The business relies on an innovative protein for spinal tissue regeneration that eliminates the need for autografts. The asset's valuation trend on GURU.Markets, where the indicator stands at 0.00, illustrates the position of this bone graft developer for trauma centers and surgeons.

This indicator assesses the business's liquidity stability by comparing liabilities due within one year to total equity, allowing investors to determine the company's reliance on short-term refinancing; an analysis of the short-term debt-to-equity ratio for Bone Biologics (BBLG) demonstrates financial flexibility as it integrates biomaterials into surgical standards, confirming its ability to maintain a steady stream of government contracts without a critical debt burden.